The cancer anorexia/weight loss syndrome: Therapeutic challenges

Karin F. Giordano, Aminah Jatoi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The cancer anorexia/weight loss syndrome is characterized by loss of weight, loss of appetite, overall decline in quality of life, and shortened survival in patients with advanced incurable cancer. It is highly prevalent. To date, treatment options that have been firmly established with good scientific evidence are limited to progestational agents and corticosteroids, both of which have been demonstrated to improve appetite but have otherwise failed to have a favorable impact on some of the other aspects of this syndrome. As the mechanisms behind this syndrome are further elucidated, more effective therapeutic strategies will likely emerge.

Original languageEnglish (US)
Pages (from-to)271-276
Number of pages6
JournalCurrent Oncology Reports
Volume7
Issue number4
StatePublished - Jul 2005

Fingerprint

Anorexia
Weight Loss
Appetite
Neoplasms
Progestins
Adrenal Cortex Hormones
Therapeutics
Quality of Life
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The cancer anorexia/weight loss syndrome : Therapeutic challenges. / Giordano, Karin F.; Jatoi, Aminah.

In: Current Oncology Reports, Vol. 7, No. 4, 07.2005, p. 271-276.

Research output: Contribution to journalArticle

@article{35dad74a404e43e2a131d6f41ed1853f,
title = "The cancer anorexia/weight loss syndrome: Therapeutic challenges",
abstract = "The cancer anorexia/weight loss syndrome is characterized by loss of weight, loss of appetite, overall decline in quality of life, and shortened survival in patients with advanced incurable cancer. It is highly prevalent. To date, treatment options that have been firmly established with good scientific evidence are limited to progestational agents and corticosteroids, both of which have been demonstrated to improve appetite but have otherwise failed to have a favorable impact on some of the other aspects of this syndrome. As the mechanisms behind this syndrome are further elucidated, more effective therapeutic strategies will likely emerge.",
author = "Giordano, {Karin F.} and Aminah Jatoi",
year = "2005",
month = "7",
language = "English (US)",
volume = "7",
pages = "271--276",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - The cancer anorexia/weight loss syndrome

T2 - Therapeutic challenges

AU - Giordano, Karin F.

AU - Jatoi, Aminah

PY - 2005/7

Y1 - 2005/7

N2 - The cancer anorexia/weight loss syndrome is characterized by loss of weight, loss of appetite, overall decline in quality of life, and shortened survival in patients with advanced incurable cancer. It is highly prevalent. To date, treatment options that have been firmly established with good scientific evidence are limited to progestational agents and corticosteroids, both of which have been demonstrated to improve appetite but have otherwise failed to have a favorable impact on some of the other aspects of this syndrome. As the mechanisms behind this syndrome are further elucidated, more effective therapeutic strategies will likely emerge.

AB - The cancer anorexia/weight loss syndrome is characterized by loss of weight, loss of appetite, overall decline in quality of life, and shortened survival in patients with advanced incurable cancer. It is highly prevalent. To date, treatment options that have been firmly established with good scientific evidence are limited to progestational agents and corticosteroids, both of which have been demonstrated to improve appetite but have otherwise failed to have a favorable impact on some of the other aspects of this syndrome. As the mechanisms behind this syndrome are further elucidated, more effective therapeutic strategies will likely emerge.

UR - http://www.scopus.com/inward/record.url?scp=23344454966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23344454966&partnerID=8YFLogxK

M3 - Article

C2 - 15946586

AN - SCOPUS:23344454966

VL - 7

SP - 271

EP - 276

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 4

ER -